logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore

prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Nath Bio-Genes (India) Ltd

Nath Bio-Genes (India)

Small Cap451 EmployeesIPO 2014
Current Price
140.77
3.31 (2.41%)Updated
NSE :NATHBIOGEN
BSE :537291
Valuation vs Sector
P/E Ratio
6.61vs 32.98
P/B Ratio
0.42vs 8.13
Div Yield
1.37%vs 1.79%
Today's Range
134
140.77
indicator
145.5
52 Week Range
52W Low126.15
52W High238.69
140.77
indicator
Downside11.59%
Upside69.56%

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
283.35 Cr
Market Cap
Total market value of company
P/E Ratio
6.57
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
0.46
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
22.62
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
0.64%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
6.96%
ROCE
Return on Capital Employed. >15% is good
Net Margin
9.68%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-5.23%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
5.45%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
16.30%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
5.61%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.19
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
339.08
Book Value
Net asset value per share
Dividend Yield
1.37%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
45.60%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

4 points
  • The company trades at an attractive Price-to-Earnings (P/E) ratio of 8.05, which is notably below the sector P/E of 8.77 and most peers, suggesting a potentially undervalued stock.
  • With a book value of 339.00 and a Price-to-Book (P/B) ratio of 0.50, the stock is trading significantly below its intrinsic asset value, offering a potential margin of safety for investors.

Weaknesses

4 points
  • Profitability ratios are low, with ROE at 6.23% and ROCE at 6.96%, indicating inefficient capital utilization compared to industry peers and potentially weaker operational performance.
  • Institutional investor confidence appears to be declining, with DII holdings significantly dropping from 4.62% to 0.76% over the past year, signaling reduced interest from domestic institutions.

Opportunities

3 points
  • Operating in the 'Other Agricultural Products' and 'Fast Moving Consumer Goods' sectors, the company is well-positioned to capitalize on increasing demand for agricultural inputs and consumer goods.
  • Nath Bio-Genes' P/E ratio of 8.05 is significantly lower than peers like LT Foods (23.64) and Kaveri Seed (17.08), suggesting a potential for re-rating if its performance improves.

Threats

3 points
  • The company faces intense competition from peers such as Kaveri Seed (ROCE 20.08%) and LT Foods (ROCE 19.18%), which exhibit significantly higher profitability and operational efficiency.
  • Operating in 'Other Agricultural Products', the company is highly susceptible to seasonal variations, unpredictable weather patterns, and evolving government policies impacting the agricultural sector.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4169.18+₹28.41+20.18%
R3157.68+₹16.91+12.01%
R2151.59+₹10.82+7.69%
R1146.18+₹5.41+3.84%
PIVOT140.09-0.68-0.48%
CURRENT140.77--
S1111.68-₹29.09-20.66%
S2123.18-₹17.59-12.50%
S3128.59-₹12.18-8.65%
S4134.68-₹6.09-4.33%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.22L
(02 Apr 2026)
-29.7% vs avg
Delivery %
66.5%
(02 Apr 2026)
-5.8% vs avg
Avg Volume (20D)
0.31L
(04 Mar - 02 Apr)
20-day average
Avg Delivery %
72.3%
(04 Mar - 02 Apr)
Trend ↓
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Godrej Agrovet Ltd
12,413.88 ₹ Cr
Best Profit Growth
Harrisons Malayalam Ltd
206.00 %
Highest Dividend Yield
Godrej Agrovet Ltd
1.70 %

Peer Comparison

Company Name
GODREJAGRO
Godrej Agrovet Ltd
HARRMALAYA
Harrisons Malayalam Ltd
INDOUS
Indo US Bio-Tech Ltd
MGEL
Mangalam Global Enterprise Ltd

About

NATHBIOGEN

Nath Bio-Genes (India) Ltd

Nath Bio-Genes (India) Limited is a prominent player in the Indian agricultural sector, specializing in the production, processing, and marketing of hybrid and genetically modified (GM) seeds. Their business model encompasses both domestic and international markets, contributing to a diverse and expansive reach within the industry. The company's activities are primarily focused on providing a comprehensive range of seeds tailored to various agricultural needs.

The company's operations are structured around two core segments: Agricultural Activities and Trading Activities. The Agricultural Activities segment focuses on the cultivation and processing of a wide spectrum of seeds. This includes fiber and oil seeds such as cotton and mustard, which are crucial components of the textile and edible oil industries, respectively. In addition, they offer seeds for various field crops, encompassing cereals like bajra, corn, paddy, wheat, and jowar, contributing to food security and agricultural output. Their portfolio extends to fruit seeds and a comprehensive selection of vegetable seeds, covering a wide variety of popular crops.

Beyond seeds, Nath Bio-Genes also offers a line of crop protection supplements under the brand names WINPro GOLii, WINall, and Win Chi Win. These supplements are designed to enhance crop health, yield, and resilience, addressing critical aspects of modern agriculture. Furthermore, the company supplies forage seeds under the NUTRIMAX GOLD and NUTRIMAX brands, catering to livestock farming and related industries. This diversification into related agricultural products enhances their market positioning and strengthens their customer relationships.

The Trading Activities segment complements their agricultural production, encompassing the buying and selling of agricultural commodities and related products. This vertical integrates with their seed production and crop protection supplement businesses, facilitating efficient market access and supply chain management. The integration between the agricultural and trading activities allows for a more holistic approach to serving the agricultural market, from seed production to post-harvest management and distribution.

Established in 1979 and headquartered in Mumbai, India, Nath Bio-Genes (India) Limited has cultivated a significant presence in the agricultural landscape. Their extensive product portfolio, coupled with their focus on both domestic and international markets, positions them as a key contributor to India's agricultural sector and a significant player in the global seed market.

COMPANY FACTS - NATHBIOGEN

Registered Address

1, Chateau Windsor,, 86 Veer Nariman Road,, Churchgate

Mumbai

MAHARASHTRA

IN

Tel: 912222871001

Website:https://nathbiogenes.com/

Company Details

Group: Food, Beverage & Tobacco

Sector: Consumer Staples

Industry: Food Products

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 451

IPO Date: 28/01/2014

MANAGEMENT - NATHBIOGEN

Mrs. Jeevanlata Kagliwal

Additional Director

Mr. Amol Gupta

Chief Financial Officer

Mr. Dhiraj Rathi

Compliance Officer, Company Secretary

Mr. Satish Kagliwal

Managing Director, Director

Mrs. Sweta Kagliwal

Non-Executive Director

Mr. Madhukar Deshpande

Additional Independent Director

Mr. Vadla Nagabhushanam

Additional Independent Director

Mr. Hitesh Purohit

Additional Independent Director

Investor Questions Answered

Nath Bio-Genes (India) Ltd (NATHBIOGEN) Stock FAQs

Get answers to the most common questions about Nath Bio-Genes (India) Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Nath Bio-Genes (India) Ltd (NATHBIOGEN) is ₹140.77. Today, the stock has gained by ₹3.31 (2.41%), trading in a range of ₹134 to ₹145.5. The stock opened at ₹137.46 with a trading volume of 21,503 shares.
Nath Bio-Genes (India) Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹283.35 crores, P/E ratio of 6.57, ROE of 0.64%, and ROCE of 6.96%. The dividend yield stands at 1.37%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Nath Bio-Genes (India) Ltd (NATHBIOGEN) is ₹238.69, while the 52-week low is ₹126.15. Currently trading at ₹140.77, the stock is 13.0% away from its 52-week low and 41.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Nath Bio-Genes (India) Ltd stock at ₹140.77 depends on multiple factors. The stock is currently trading with a P/E ratio of 6.57 and P/B ratio of N/A. Today's performance shows a gain of 2.41%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Nath Bio-Genes (India) Ltd offers a dividend yield of 1.37%, which means for every ₹100 invested at the current price of ₹140.77, you can expect to receive approximately ₹1.37 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Nath Bio-Genes (India) Ltd's key financial metrics include: P/E Ratio: 6.57, P/B Ratio: N/A, ROE: 0.64%, ROCE: 6.96%, Dividend Yield: 1.37%, EPS: ₹22.62, Book Value: ₹339.08, Debt-to-Equity: 0.19, and Current Ratio: N/A. The company's market cap stands at ₹283.35 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Nath Bio-Genes (India) Ltd stock opened at ₹137.46 and is currently trading at ₹140.77, showing a gain of ₹3.31 (2.41%). The intraday high is ₹145.5 and low is ₹134. The trading volume stands at 21,503 shares, indicating moderate market participation today.
Nath Bio-Genes (India) Ltd has a Price-to-Earnings (P/E) ratio of 6.57, which means investors are willing to pay ₹6.57 for every ₹1 of earnings. With an EPS of ₹22.62, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Nath Bio-Genes (India) Ltd has a market capitalization of ₹283.35 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹140.77) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Nath Bio-Genes (India) Ltd has a book value of ₹339.08 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹140.77, which is 58.5% below the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Nath Bio-Genes (India) Ltd has a Return on Equity (ROE) of 0.64% and Return on Capital Employed (ROCE) of 6.96%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Nath Bio-Genes (India) Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Nath Bio-Genes (India) Ltd has a debt-to-equity ratio of 0.19, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Nath Bio-Genes (India) Ltd has an Earnings Per Share (EPS) of ₹22.62, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹140.77 and P/E ratio of 6.57, investors are paying 6.57 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Nath Bio-Genes (India) Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Nath Bio-Genes (India) Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Nath Bio-Genes (India) Ltd stock, consider: 1) Fundamental Analysis - Review P/E (6.57), ROE (0.64%), debt-to-equity (0.19), and growth rates. 2) Technical Analysis - Check 52-week range (₹126.15 - ₹238.69), moving averages, and chart patterns. 3) Valuation - Compare current price (₹140.77) with book value (₹339.08) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Nath Bio-Genes (India) Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹140.77 is 1308x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Nath Bio-Genes (India) Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹126.15 - ₹238.69). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.19 indicates leverage. 4) Liquidity Risk - Based on trading volume of 21,503 shares. 5) Valuation Risk - P/E of 6.57 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Nath Bio-Genes (India) Ltd operates in the industry with key metrics: P/E ratio of 6.57, ROE of 0.64%, market cap of ₹283.35 crores, and dividend yield of 1.37%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.19), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Nath Bio-Genes (India) Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹140.77, with a 52-week range of ₹126.15 to ₹238.69. Based on fundamentals like P/E (6.57), ROE (0.64%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Nath Bio-Genes (India) Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹140.77. 2) Fundamental Deterioration - Declining ROE (currently 0.64%), increasing debt (D/E: 0.19), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Nath Bio-Genes (India) Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 1.37%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.